Josh Genuth, Author at PsyNews.com

Home Authors Posts by Watertime

426 POSTS 0 COMMENTS

How Psychedelics Can Help Palliative and End-of-Life Care

Five Talking Points for People Skeptical of Psychedelic Therapy

The Future of MDMA Therapy: Promising Next Steps

How Psychedelics Can Treat PTSD

This is the Difference Between Psilocybin and LSD

So, You Want to Participate in a Psychedelic Clinical Trial

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

How Red Light Holland Is Bringing Psilocybin Truffles Mainstream

The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters

Interview With Yaron Conforti, Novamind

1...373839...43 Page 38 of 43

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime